Bristol-Myers Squibb 3Q Revenues:  $5.3 billion (+7) 3Q Earnings:  $856 million (-30%) YTD Revenues: $15.3 billion (+8%)    YTD Earnings: $3.3 billion (-6%) Comments: Eliquis sales were up 39% in the quarter to $1.2 billion. Opdivo sales were $1.3 billion, up 38%. Yervoy sales were up 13% to $323 million. Orencia sales were up 10% to $632 million. Sprycel sales were up 8% to $509 million. Hep C Franchise sales were down 81% to $73 million. Baraclude sales were down 14% to $264 million. Sust...